Realizing the Translational Potential of Telomere Length Variation as a Tissue-Based Prognostic Marker for Prostate Cancer
Abstract
We are testing, in prospective studies from Hopkins (Brady) and Harvard (PHS, HPFS), whether the combination of telomere length variability in prostate cancer cells and short telomere length in cancer-associated stromal cells is an independent prognostic indicator of poor prostate cancer outcome. In Year 3, we continued our progress towards a fully optimized protocol for automated slide scanning and multi-channel acquisition of fluorescent images using the TissueFAXS Plus microscopy workstation and TissueFAXS 4.0 software (Tissue Gnostics). We are nowable to reliably scan and analyze an entire prostate TMA. We demonstrated our ability to quantitate the telomere signals on a per nucleus basis in both the cancer and cancer-associated stromal (CAS) cells. We developed a set of criteria we will use to decide whether the currently established automated method is sufficiently optimized tomove forward with Tasks 5, 6, and 7 in Year 4. Given what we have observed and documented during the automation and optimization process in Year 3, we do not expect that we will need to revert to the manual method of telomere length determination to complete the remaining tasks.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- AD1002908
Entities
People
- Elizabeth A Platz
Organizations
- Johns Hopkins University